 |
|
Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer—Invited Critique
Michael E. Zenilman, MD
Arch Surg. 2008;143(11):1097.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Min et al from Seoul nicely show that the expression of COX-2 protein in colon cancer specimens inversely correlates with the tumor's response to adjuvant CRT. While I cannot tell if this is really a prospective study or a retrospective analysis of 30 consecutive patients with stage II and III disease, it is work that pushes the envelope of diagnostic tests to the next—molecular—level.
It has been 10 years since the landmark Swedish study demonstrated that preoperative adjuvant CRT improved survival in rectal cancer.1 The authors are currently asking which patients will really benefit from the therapy. The answer will be at the molecular level.
The hunt for molecular markers in colon cancer has yielded many candidate genes and protein products. Last year in the journal Science, Sjöblom et al2 identified 69 mutated protein-coding genes in colorectal cancer. In fact, each individual cancer that was . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer
Byung Soh Min, Yoon Jung Choi, Hong Ryull Pyo, Hogeun Kim, JinSil Seong, Hyun Cheol Chung, Sun Young Rha, and Nam Kyu Kim
Arch Surg. 2008;143(11):1091-1097.
ABSTRACT
| FULL TEXT
|
